# A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

> **NCT04642365** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 49 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RO7296682
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04642365
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-04
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-01-04
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** The sponsor decided to terminate the study early, due to recruitment challenges for Part II and, based on the totality of data generated with a low likelihood of achieving the targeted efficacy, to open Part III.
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04642365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04642365, "A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04642365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*